When Results Also Allow the Opposite Conclusion…
The straight forward DANAMI-3–PRIMULTI trial showed that patients with ST-elevation myocardial infarction and multivessel disease, who had timely primary percutaneous coronary intervention, benefitted from fractional flow reserve–guided revascularizations of lesions…